Successful and Well-Tolerated Second Line Therapy with Cetuximab, Irinotecan, and Raltitrexed in Progressive Liver Disease Due to Metastatic Colon Cancer

Geurs, F.; Vandewaeter, S.; Ponette, S.; Ponette, J.; Knape, S.; Demetter, Pieter

doi:10.1007/s12029-009-9060-4

Cited by 3 publications

(1 citation statement)

References 14 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This knowledge has been drawn from a deeper insight into the pharmacology of drug clearance in cancer patients with liver dysfunction. 10 Apart from case reports, 11 however, there are no reports of series of patients presenting with severe jaundice, due to metastatic involvement of the liver, in which the treatment and outcome are summarized. We report here the first case series in this patient group, in which all patients were treated the same way with weekly cisplatin, until recovery of liver function, or death.…”

Section: Introductionmentioning

confidence: 99%

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

Gabrovska¹,

Geurs²,

Ponette³

et al. 2009

HMER

View full text Add to dashboard Cite

Few data are available on patient management in jaundice caused by liver metastases of solid tumors (nonbreast and noncolon origin). We report the first patient series consecutively treated with cisplatin weekly in patients with severe jaundice and liver failure due to underlying metastatic neoplasms. In 4 out of 8 cases, liver function tests were reversed and jaundice disappeared, permitting subsequent standard chemotherapy. The other 4 patients died 3 to 5 weeks after admission, illustrating the extent and severity of the underlying neoplasm.

show abstract

Section: Introductionmentioning

confidence: 99%

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

Gabrovska¹,

Geurs²,

Ponette³

et al. 2009

HMER

View full text Add to dashboard Cite

show abstract

First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study

Gallois

Hafliger

Auclin

et al. 2022

Digestive and Liver Disease

View full text Add to dashboard Cite

Raltitrexed Inhibits HepG2 Cell Proliferation via G₀/G₁ Cell Cycle Arrest

Zhao

Zhang²,

Sun³

et al. 2016

oncol res

View full text Add to dashboard Cite

Raltitrexed (RTX) is an antimetabolite drug used as a chemotherapeutic agent for treating colorectal cancer, malignant mesothelioma, and gastric cancer. The antitumor capacity of RTX is attributed to its inhibitory activity on thymidylate synthase (TS), a key enzyme in the synthesis of DNA precursors. The current study is aimed at investigating the potential antitumor effects of RTX in liver cancer. Using the HepG2 cell line as an in vitro model of liver cancer, we evaluated the effects of RTX on cell proliferation employing both a WST-8 assay and a clone formation efficiency assay. In addition, we monitored the ultrastructure changes of HepG2 cells in response to RTX with transmission electric microscopy. To investigate the mechanism underlying the regulation of cell proliferation by RTX, we analyzed cell cycle using cell flow cytometry. Moreover, real-time PCR and Western blot analyses were conducted to examine expression levels of cell cycle regulatory proteins cyclin A and cyclin-dependent kinase 2 (CDK2), as well as their mediators tumor suppressor genes p53 and p16. Our results demonstrate that RTX inhibits HepG2 proliferation by arresting the cell cycle at G0/G1. This cell cycle arrest function was mediated via downregulation of cyclin A and CDK2. The observed elevated expression of p53 and p16 by RTX may contribute to the reduction of cyclin A/CDK2. Our study indicates that RTX could serve as a potential chemotherapeutic agent in the treatment of hepatocellular carcinoma.

show abstract

Successful and Well-Tolerated Second Line Therapy with Cetuximab, Irinotecan, and Raltitrexed in Progressive Liver Disease Due to Metastatic Colon Cancer

Cited by 3 publications

References 14 publications

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study

Raltitrexed Inhibits HepG2 Cell Proliferation via G₀/G₁ Cell Cycle Arrest

Contact Info

Product

Resources

About

Successful and Well-Tolerated Second Line Therapy with Cetuximab, Irinotecan, and Raltitrexed in Progressive Liver Disease Due to Metastatic Colon Cancer

Cited by 3 publications

References 14 publications

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors

First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study

Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest

Contact Info

Product

Resources

About

Raltitrexed Inhibits HepG2 Cell Proliferation via G₀/G₁ Cell Cycle Arrest